Targeting prostate cancer stem cells with T cell immunotherapy

Screening cancer patients for microsatellite instability (MSI) can provide pathologists, oncologists, and patients with information that characterizes tumors to help guide care and make more informed decisions.

Virtual or “siteless” clinical trials allow trial coordinators and patients to conduct clinical study visits via online video calls and collect data via handheld or wearable devices. In addition, virtual trials increase the size and diversity of the patient pool, accelerate recruiting, and generate more informative, clinically-relevant data that is accepted by regulatory agencies. However, moving from traditional to virtual trials presents challenges as clinical trial sponsors learn how to design, execute, and complete effective virtual trials. To assure success, trial sponsors need to better understand the digital tools and platforms used in virtual trials, how to manage the data collection they enable, and the pitfalls to avoid. In this webinar, Bernard Munos, a pioneering pharmaceutical industry innovator, and Transparency Life Sciences co-founder Dr. Tomasz Sablinski will provide an overview of the strategies leaders are finding helpful in adopting and adapting to virtual trials.

There are approximately 7,000 distinct rare diseases affecting 350 million people worldwide, approximately 80 percent of which are caused by faulty genes. The US Food and Drug Administration (FDA) has more than 700 active Investigational New Drug Applications (INDs) for gene and cell therapies and in 2017, the FDA approved two cell-based gene therapies and it is anticipated that gene therapy will become a mainstay treatment for many rare diseases.

In this SelectScience webinar, Robert Stroud, Chief of Perfusion at the Maimonides Medical Center, will focus on the cardiovascular operating room (CVOR) and the challenges experienced throughout the various procedures.